Skip to main content
Erschienen in: Inflammation 3/2015

01.06.2015

GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes

verfasst von: Kathleen Dungan, Philip Binkley, Kwame Osei

Erschienen in: Inflammation | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

GlycA is a nuclear magnetic resonance-derived signal that originates from oligosaccharide chains of acute phase proteins. The objective of this study is to characterize GlycA levels in hospitalized non-critically ill patients with type 2 diabetes. This study evaluated traditional and novel (GlycA) inflammatory markers among 121 patients who were stratified by admission diagnoses: congestive heart failure (CHF), cardiac non-CHF (CARD), infection (INF), and other (OTH). HbA1c was similar across groups (8.0–9.2 %, p = 0.20). Inflammatory markers were elevated but varied significantly across disease categories, with the highest values of interleukin-6 (IL-6), c-reactive protein (CRP), and GlycA in the INF group and the highest tumor necrosis factor-α and intracellular adhesion molecule-1 levels in CHF group. GlycA was associated with higher IL-6 and CRP, lower hemoglobin, and lower glomerular filtration rate. GlycA and other inflammatory markers were not significantly associated with admission glucose or HbA1c. Among hospitalized non-critically ill patients with type 2 diabetes, GlycA was highest in INF patients and was associated with IL-6 and CRP. None of the markers were significant predictors of glucose control.
Literatur
2.
Zurück zum Zitat Umpierrez, G.E., R. Hellman, M.T. Korytkowski, M. Kosiborod, G.A. Maynard, V.M. Montori, J.J. Seley, and G. Van den Berghe. 2012. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline; Endocrine Society. Journal of Clinical Endocrinology and Metabolism 97(1): 16–38.CrossRefPubMed Umpierrez, G.E., R. Hellman, M.T. Korytkowski, M. Kosiborod, G.A. Maynard, V.M. Montori, J.J. Seley, and G. Van den Berghe. 2012. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline; Endocrine Society. Journal of Clinical Endocrinology and Metabolism 97(1): 16–38.CrossRefPubMed
3.
Zurück zum Zitat Umpierrez, G.E., S.D. Isaacs, N. Bazargan, X. You, L.M. Thaler, and A.E. Kitabchi. 2002. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. Journal of Clinical Endocrinology and Metabolism 87(3): 978–82.CrossRefPubMed Umpierrez, G.E., S.D. Isaacs, N. Bazargan, X. You, L.M. Thaler, and A.E. Kitabchi. 2002. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. Journal of Clinical Endocrinology and Metabolism 87(3): 978–82.CrossRefPubMed
4.
Zurück zum Zitat Menzin, J., J.R. Korn, J. Cohen, F. Lobo, B. Zhang, M. Friedman, and P.J. Neumann. 2010. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. Journal of Managed Care Pharmacy 16(4): 264–75.PubMed Menzin, J., J.R. Korn, J. Cohen, F. Lobo, B. Zhang, M. Friedman, and P.J. Neumann. 2010. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. Journal of Managed Care Pharmacy 16(4): 264–75.PubMed
5.
Zurück zum Zitat Falciglia, M., R.W. Freyberg, P.L. Almenoff, D.A. D’Alessio, and M.L. Render. 2009. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Critical Care Medicine 37(12): 3001–9.CrossRefPubMedCentralPubMed Falciglia, M., R.W. Freyberg, P.L. Almenoff, D.A. D’Alessio, and M.L. Render. 2009. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Critical Care Medicine 37(12): 3001–9.CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Pickup, J.C., and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241–8.CrossRefPubMed Pickup, J.C., and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241–8.CrossRefPubMed
7.
Zurück zum Zitat Clement, S., S.S. Braithwaite, M.F. Magee, A. Ahmann, E.P. Smith, R.G. Schafer, I.B. Hirsch, and American Diabetes Association Diabetes in Hospitals Writing Committee. 2004. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27(2): 553–91.CrossRefPubMed Clement, S., S.S. Braithwaite, M.F. Magee, A. Ahmann, E.P. Smith, R.G. Schafer, I.B. Hirsch, and American Diabetes Association Diabetes in Hospitals Writing Committee. 2004. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27(2): 553–91.CrossRefPubMed
8.
Zurück zum Zitat Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340: 448–54.CrossRefPubMed Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340: 448–54.CrossRefPubMed
9.
Zurück zum Zitat Ceciliani, F., and V. Pocacqua. 2007. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Current Protein and Peptide Science 8: 91–108.CrossRefPubMed Ceciliani, F., and V. Pocacqua. 2007. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Current Protein and Peptide Science 8: 91–108.CrossRefPubMed
10.
Zurück zum Zitat Dijk, W., G. Turner, and A. Mackiewicz. 1994. Changes in glycosylation of acute-phase proteins in health and disease: occurrence, regulation and function. Glycoconjugate Journal 1: 5–14.CrossRef Dijk, W., G. Turner, and A. Mackiewicz. 1994. Changes in glycosylation of acute-phase proteins in health and disease: occurrence, regulation and function. Glycoconjugate Journal 1: 5–14.CrossRef
11.
Zurück zum Zitat Bell, J.D., J.C. Brown, J.K. Nicholson, and P.J. Sadler. 1987. Assignment of resonances for ‘acute-phase’ glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Letters 215: 311–5.CrossRefPubMed Bell, J.D., J.C. Brown, J.K. Nicholson, and P.J. Sadler. 1987. Assignment of resonances for ‘acute-phase’ glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Letters 215: 311–5.CrossRefPubMed
12.
Zurück zum Zitat Otvos J, Shalaurova I, Wolak-Dinsmore J, Matyus S. 2013. GlycA and GlycB: novel NMR markers of systemic inflammation. American Association of Clinical Chemistry Poster #B-255. Otvos J, Shalaurova I, Wolak-Dinsmore J, Matyus S. 2013. GlycA and GlycB: novel NMR markers of systemic inflammation. American Association of Clinical Chemistry Poster #B-255.
13.
Zurück zum Zitat Akinkuolie A, Pradhan AD, Ridker PM, Mora S. 2013. Novel protein glycan derived biomarker is associated with incident diabetes. American Heart Association Poster 18807. Akinkuolie A, Pradhan AD, Ridker PM, Mora S. 2013. Novel protein glycan derived biomarker is associated with incident diabetes. American Heart Association Poster 18807.
14.
Zurück zum Zitat Akinkuolie A.O., Buring J.E., Ridker P.M., Mora S. 2013. Novel protein glycan derived marker of systemic inflammation is associated with incident cardiovascular disease. American Heart Association, Poster 18739. Akinkuolie A.O., Buring J.E., Ridker P.M., Mora S. 2013. Novel protein glycan derived marker of systemic inflammation is associated with incident cardiovascular disease. American Heart Association, Poster 18739.
15.
Zurück zum Zitat Kriat, M., J. Vion-Dury, R. Fayre, D. Maraninchi, J.R. Harlé, S. Confort-Gouny, M. Sciaky, E. Fontanarava, P. Viout, and P.J. Cozzone. 1991. Variations of plasma sialic acid and N-acetylglucosamine levels in cancer, inflammatory diseases and bone marrow transplantation: a proton NMR spectroscopy study. Biochimie 73: 99–104.CrossRefPubMed Kriat, M., J. Vion-Dury, R. Fayre, D. Maraninchi, J.R. Harlé, S. Confort-Gouny, M. Sciaky, E. Fontanarava, P. Viout, and P.J. Cozzone. 1991. Variations of plasma sialic acid and N-acetylglucosamine levels in cancer, inflammatory diseases and bone marrow transplantation: a proton NMR spectroscopy study. Biochimie 73: 99–104.CrossRefPubMed
16.
Zurück zum Zitat Dungan, K.M., C. Sagrilla, M. Abdel-Rasoul, and K. Osei. 2013. Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes. Diabetes Care 36(11): 3476–82. Dungan, K.M., C. Sagrilla, M. Abdel-Rasoul, and K. Osei. 2013. Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes. Diabetes Care 36(11): 3476–82.
17.
Zurück zum Zitat Dungan K.M., Osei K., Gaillard T., Moore J., Binkley P. 2014. A comparison of continuous intravenous insulin and subcutaneous insulin among patients with type 2 diabetes and congestive heart failure exacerbation. Diabetes Metab Res Rev in press. Dungan K.M., Osei K., Gaillard T., Moore J., Binkley P. 2014. A comparison of continuous intravenous insulin and subcutaneous insulin among patients with type 2 diabetes and congestive heart failure exacerbation. Diabetes Metab Res Rev in press.
18.
Zurück zum Zitat Modification of Diet in Renal Disease Study Group. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine 130(6): 461–70. Modification of Diet in Renal Disease Study Group. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine 130(6): 461–70.
19.
Zurück zum Zitat Braunwald, E. 2008. Biomarkers in heart failure. New England Journal of Medicine 358: 2148–2159. Braunwald, E. 2008. Biomarkers in heart failure. New England Journal of Medicine 358: 2148–2159.
20.
Zurück zum Zitat Burger, A.J., and D. Aronson. 2001. Blunted sympathetic response in diabetic patients with decompensated congestive heart failure. International Journal of Cardiology 81: 243–249.CrossRefPubMed Burger, A.J., and D. Aronson. 2001. Blunted sympathetic response in diabetic patients with decompensated congestive heart failure. International Journal of Cardiology 81: 243–249.CrossRefPubMed
21.
Zurück zum Zitat Romeo, R., C. Scalisi, L. Tafuri, A. Romeo, D. Maugeri, and R. Sorace. 2010. Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics. Archives of Gerontology and Geriatrics 50(1): 101–4. Romeo, R., C. Scalisi, L. Tafuri, A. Romeo, D. Maugeri, and R. Sorace. 2010. Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics. Archives of Gerontology and Geriatrics 50(1): 101–4.
22.
Zurück zum Zitat Jankowska, E.A., P. Ponikowski, M.F. Piepoli, W. Banasiak, S.D. Anker, and P.A. Poole-Wilson. 2006. Autonomic imbalance and immune activation in chronic heart failure—pathophysiological links. Cardiovascular Research 70: 434–445. Jankowska, E.A., P. Ponikowski, M.F. Piepoli, W. Banasiak, S.D. Anker, and P.A. Poole-Wilson. 2006. Autonomic imbalance and immune activation in chronic heart failure—pathophysiological links. Cardiovascular Research 70: 434–445.
23.
Zurück zum Zitat Gruzdeva, O., E. Uchasova, Y. Dyleva, E. Belik, E. Shurygina, and O. Barbarash. 2013. Insulin resistance and inflammation markers in myocardial infarction. Journal of Inflammation Research 6: 83–90.PubMedCentralPubMed Gruzdeva, O., E. Uchasova, Y. Dyleva, E. Belik, E. Shurygina, and O. Barbarash. 2013. Insulin resistance and inflammation markers in myocardial infarction. Journal of Inflammation Research 6: 83–90.PubMedCentralPubMed
24.
Zurück zum Zitat Heo, J.M., J.H. Park, J.H. Kim, S.H. You, J.S. Kim, C.M. Ahn, S.J. Hong, K.H. Shin, and D.S. Lim. 2012. Comparison of inflammatory markers between diabetic and nondiabetic ST segment elevation myocardial infarction. Journal of Cardiology 60(3): 204–9.CrossRefPubMed Heo, J.M., J.H. Park, J.H. Kim, S.H. You, J.S. Kim, C.M. Ahn, S.J. Hong, K.H. Shin, and D.S. Lim. 2012. Comparison of inflammatory markers between diabetic and nondiabetic ST segment elevation myocardial infarction. Journal of Cardiology 60(3): 204–9.CrossRefPubMed
25.
Zurück zum Zitat Liao, M.T., C.C. Sung, K.C. Hung, C.C. Wu, L. Lo, and K.C. Lu. 2012. Insulin resistance in patients with chronic kidney disease. Journal of Biomedicine and Biotechnology 2012: 691369.PubMedCentralPubMed Liao, M.T., C.C. Sung, K.C. Hung, C.C. Wu, L. Lo, and K.C. Lu. 2012. Insulin resistance in patients with chronic kidney disease. Journal of Biomedicine and Biotechnology 2012: 691369.PubMedCentralPubMed
26.
Zurück zum Zitat Karavanaki, K., K. Kakleas, S. Georga, A. Bartzeliotou, G. Mavropoulos, M. Tsouvalas, A. Vogiatzi, I. Papassotiriou, and C. Karayianni. 2012. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis. Clinical Biochemistry 45(16–17): 1383–8.CrossRefPubMed Karavanaki, K., K. Kakleas, S. Georga, A. Bartzeliotou, G. Mavropoulos, M. Tsouvalas, A. Vogiatzi, I. Papassotiriou, and C. Karayianni. 2012. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis. Clinical Biochemistry 45(16–17): 1383–8.CrossRefPubMed
27.
Zurück zum Zitat Turina, M., D.E. Fry, and H.C. Polk Jr. 2005. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Critical Care Medicine 33(7): 1624–33.CrossRefPubMed Turina, M., D.E. Fry, and H.C. Polk Jr. 2005. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Critical Care Medicine 33(7): 1624–33.CrossRefPubMed
28.
Zurück zum Zitat Fantin Sde, S., M.V. Wainstein, C.A. Polanczyk, P. Ledur, C.M. Lazzari, C. Klein, F.S. Hackenhaar, M.S. Benfato, and B.D. Schaan. 2011. Inflammatory and oxidative stress markers after intravenous insulin in percutaneous coronary intervention with stent in type 2 diabetes mellitus: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 96(2): 478–85.CrossRefPubMed Fantin Sde, S., M.V. Wainstein, C.A. Polanczyk, P. Ledur, C.M. Lazzari, C. Klein, F.S. Hackenhaar, M.S. Benfato, and B.D. Schaan. 2011. Inflammatory and oxidative stress markers after intravenous insulin in percutaneous coronary intervention with stent in type 2 diabetes mellitus: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 96(2): 478–85.CrossRefPubMed
29.
Zurück zum Zitat Bree, F., G. Houin, J. Barre, J.L. Moretti, V. Wirquin, and J.P. Tillement. 1986. Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein. Clinical Pharmacokinetics 11(4): 336–342.CrossRefPubMed Bree, F., G. Houin, J. Barre, J.L. Moretti, V. Wirquin, and J.P. Tillement. 1986. Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein. Clinical Pharmacokinetics 11(4): 336–342.CrossRefPubMed
30.
Zurück zum Zitat Jones, E.A., J. Vergalla, C.J. Steer, P.R. Bradley-Moore, and J.M. Vierling. 1978. Metabolism of intact and desialylated alpha 1-antitrypsin. Clinical Science and Molecular Medicine 55(2): 139–48.PubMed Jones, E.A., J. Vergalla, C.J. Steer, P.R. Bradley-Moore, and J.M. Vierling. 1978. Metabolism of intact and desialylated alpha 1-antitrypsin. Clinical Science and Molecular Medicine 55(2): 139–48.PubMed
31.
Zurück zum Zitat Kormoczi, G.F., M.D. Saemann, C. Buchta, et al. 2006. Influence of clinical factors on the haemolysis marker haptoglobin. European Journal of Clinical Investigation 36: 202–209.CrossRefPubMed Kormoczi, G.F., M.D. Saemann, C. Buchta, et al. 2006. Influence of clinical factors on the haemolysis marker haptoglobin. European Journal of Clinical Investigation 36: 202–209.CrossRefPubMed
32.
Zurück zum Zitat Ho, K.M., and J. Lipman. 2009. An update on C-reactive protein for intensivists. Anaesthesia and Intensive Care 37(2): 234–41.PubMed Ho, K.M., and J. Lipman. 2009. An update on C-reactive protein for intensivists. Anaesthesia and Intensive Care 37(2): 234–41.PubMed
33.
Zurück zum Zitat Sidhu, R.S., and A.P. Bollon. 1993. Tumor necrosis factor activities and cancer therapy—a perspective. Pharmacology and Therapeutics 57(1): 79–128.CrossRefPubMed Sidhu, R.S., and A.P. Bollon. 1993. Tumor necrosis factor activities and cancer therapy—a perspective. Pharmacology and Therapeutics 57(1): 79–128.CrossRefPubMed
34.
Zurück zum Zitat Oda, S., H. Hirasawa, H. Shiga, K. Nakanishi, K. Matsuda, and M. Nakamua. 2005. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 29(4): 169–75.CrossRefPubMed Oda, S., H. Hirasawa, H. Shiga, K. Nakanishi, K. Matsuda, and M. Nakamua. 2005. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 29(4): 169–75.CrossRefPubMed
Metadaten
Titel
GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes
verfasst von
Kathleen Dungan
Philip Binkley
Kwame Osei
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 3/2015
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0107-8

Weitere Artikel der Ausgabe 3/2015

Inflammation 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.